C92.00

Acute myeloblastic leukemia, not having achieved remission

## Pathophysiology and Clinical Significance Acute Myeloblastic Leukemia (AML), represented by ICD-10 code C92.00 when remission has not been achieved, is a heterogeneous and aggressive hematological malignancy characterized by the clonal expansion of immature myeloid precursors (myeloblasts). These malignant cells accumulate in the bone marrow and peripheral blood, leading to a profound disruption of normal hematopoiesis. The underlying pathophysiology involves a series of genetic alterations, often referred to as the "two-hit hypothesis." Classically, this involves mutations that confer a proliferative advantage—such as those in the FLT3 or KIT genes—combined with mutations that impair myeloid differentiation, such as translocations involving the core binding factor (e.g., t(8;21)) or mutations in the NPM1 or CEBPA genes. ### Hematological Disruption The code C92.00 signifies an active disease state where the marrow is heavily infiltrated by blasts. This overcrowding leads to marrow failure, manifesting as the critical clinical triad: anemia (from suppressed erythropoiesis), neutropenia (from lack of mature neutrophils), and thrombocytopenia (from suppressed megakaryopoiesis). Unlike chronic leukemias, the progression of C92.00 is typically rapid, necessitating immediate clinical intervention to prevent life-threatening complications. ## Clinical Presentation and Diagnostic Evaluation Patients with active AML frequently present with systemic symptoms such as profound fatigue, exertional dyspnea, and weight loss. The loss of normal immune function leads to recurrent or opportunistic infections, while the lack of platelets results in easy bruising, petechiae, and epistaxis. In some cases, patients may exhibit leukostasis—a medical emergency where high blast counts increase blood viscosity, leading to pulmonary or neurological dysfunction. ### Diagnostic Criteria and Risk Stratification According to the World Health Organization (WHO) and the International Consensus Classification (ICC), a diagnosis of AML generally requires a myeloblast count of 20% or more in the bone marrow or peripheral blood. However, certain genetic markers allow for the diagnosis of AML regardless of the blast percentage. Diagnostic workup must include flow cytometry to identify myeloid surface markers (e.g., CD13, CD33, CD117), cytogenetics to identify chromosomal abnormalities, and molecular profiling for mutations that influence prognosis and treatment selection. ## Management and Standard of Care The management of C92.00 depends heavily on the patient's age, performance status, and molecular risk profile. For young or fit patients, the standard induction remains intensive chemotherapy, typically the "7+3" regimen (seven days of cytarabine and three days of an anthracycline). The goal of this phase is to achieve a Complete Remission (CR), defined as <5% blasts in the marrow. If CR is achieved, the diagnosis would transition to C92.01. ### Post-Induction and Targeted Therapy For patients who do not achieve remission after one or two cycles of induction, the disease is considered refractory. Emerging therapies have significantly altered the landscape for C92.00; for example, the addition of BCL-2 inhibitors like venetoclax to hypomethylating agents has become a standard for patients unfit for intensive chemotherapy. For high-risk or refractory cases, allogeneic hematopoietic stem cell transplantation (HSCT) remains the primary curative modality, though it requires the patient to first achieve a state of minimal residual disease negativity if possible.

Clinical Symptoms

  • Severe fatigue and generalized weakness
  • Persistent or recurrent fever
  • Easy bruising and petechiae
  • Unexplained weight loss
  • Bone and joint pain
  • Shortness of breath (dyspnea)
  • Gingival hyperplasia (swelling of gums)
  • Frequent infections (pneumonia, UTI)
  • Splenomegaly or hepatomegaly
  • Excessive sweating, particularly at night

Common Causes

  • Somatic genetic mutations (e.g., FLT3, NPM1, DNMT3A, IDH1/2)
  • Exposure to high-dose ionizing radiation
  • Long-term exposure to benzene or industrial solvents
  • Previous treatment with alkylating agents or topoisomerase II inhibitors (therapy-related AML)
  • Evolution from prior myelodysplastic syndromes (MDS)
  • Evolution from myeloproliferative neoplasms (MPN)
  • Congenital genetic syndromes (Down syndrome, Fanconi anemia, Li-Fraumeni syndrome)

Documentation & Coding Tips

Distinguish between 'not having achieved remission' and 'in relapse'.

Example: Patient with newly diagnosed Acute Myeloblastic Leukemia (AML), WHO classification AML with t(8;21), currently presenting for induction chemotherapy. Remission status: Not achieved (C92.00). Note includes plan for continuous cytarabine infusion. Plan accounts for high risk of tumor lysis syndrome (E88.3) requiring frequent labs and aggressive IV hydration.

Billing Focus: Remission status 'not achieved' is the default for new diagnoses or failed induction, critical for C92.00 selection.

Explicitly document genetic and molecular markers.

Example: Acute myeloblastic leukemia, FAB M2, FLT3-ITD positive, not having achieved remission. Cytogenetics demonstrate normal karyotype. Patient presents for Cycle 1 Day 1 of Midostaurin and Daunorubicin/Cytarabine (7+3). The molecular profile indicates a high-risk prognosis (HCC 9) necessitating intensive monitoring for myelosuppression.

Billing Focus: Specificity regarding the AML subtype (e.g., myeloblastic vs. promyelocytic) and remission status (C92.00) prevents downcoding.

Link secondary causes if the AML is therapy-related.

Example: Therapy-related acute myeloblastic leukemia (t-AML), not in remission (C92.00), following previous treatment for Stage IIIA breast cancer with alkylating agents (Z85.3). Patient presents with profound pancytopenia (D61.818) and absolute neutrophil count of 0.2. Medical decision making reflects high complexity due to treatment-refractory disease.

Billing Focus: Use C92.00 for the leukemia but ensure the therapy-related status is clearly described to support associated 'T' codes if applicable.

Document specific morphology using WHO or FAB classifications.

Example: Acute myeloblastic leukemia without maturation (FAB M1), not in remission (C92.00). Bone marrow aspirate shows 85% blasts, positive for myeloperoxidase. Associated symptoms include severe symptomatic anemia (D64.9) and thrombocytopenic bleeding (D69.6). Treatment plan involves high-dose induction.

Billing Focus: Morphology supports the 'myeloblastic' specification within the C92.0x series.

Clearly state 'In Relapse' vs 'Not Having Achieved Remission' for subsequent episodes.

Example: Patient with history of AML, status post-allogeneic stem cell transplant, now presenting with 30% blasts in peripheral blood. This represents a frank relapse (C92.02), not merely a failure to achieve initial remission (C92.00). Complicated by GVHD (D89.810) and fungal pneumonia (B44.9).

Billing Focus: Selecting C92.02 (relapse) vs C92.00 (not achieved) is crucial for accurate longitudinal tracking of the disease course.

Relevant CPT Codes

Related Diagnoses

Hierarchy